Literature DB >> 19589695

The role of b-type natriuretic peptide in heart failure management.

Phillip J Newton1, Vasiliki Betihavas, Peter Macdonald.   

Abstract

Heart failure is a complex clinical syndrome that manifests itself with signs and symptoms which are neither sensitive nor specific for the diagnosis of heart failure. Natriuretic peptides and in particular b-type natriuretic peptide (and nt-proBNP) are widely used in clinical practice around the world as a maker of heart failure. BNP is primarily released from the left ventricle in response to pressure and volume overload. The strongest evidence for the use of BNP is to rule in or rule out heart failure as cause of breathlessness in people who present to the emergency room. There is enthusiasm for use of BNP as a marker of heart failure severity as well as a predictor of outcomes in people with heart failure and trials are ongoing. Nesiritide, a recombinant form of BNP is currently being tested as a possible treatment in people with acutely decompensated heart failure.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19589695     DOI: 10.1016/j.aucc.2009.06.001

Source DB:  PubMed          Journal:  Aust Crit Care        ISSN: 1036-7314            Impact factor:   2.737


  4 in total

1.  Changes in brain natriuretic peptide are correlated with changes in global end-diastolic volume index.

Authors:  Zhongheng Zhang; Hongying Ni; Baolong Lu; Xiao Xu
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

2.  Clinical Research on Brain Natriuretic Peptide Guiding the Application of β1 Receptor Blocker in Patients with Moderate to Severe Heart Failure.

Authors:  Jiang-Jin Li; Xiao-Li Xiang; Xiao-Yi Tian; Ya-Fei Shi
Journal:  Acta Cardiol Sin       Date:  2015-01       Impact factor: 2.672

3.  Prediction of resistance to standard intravenous immunoglobulin therapy in kawasaki disease.

Authors:  Sang Min Lee; Jeong Bong Lee; Young Bin Go; Ho Young Song; Byung Jin Lee; Ji Hee Kwak
Journal:  Korean Circ J       Date:  2014-11-25       Impact factor: 3.243

4.  Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease.

Authors:  Hyo Min Park; Dong Won Lee; Myung Chul Hyun; Sang Bum Lee
Journal:  Korean J Pediatr       Date:  2013-02-25
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.